Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HMPL-A83 injection
HMPL-A83 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HMPL-A83 injection | DRUG | Day 1,8,15,22 dose; 28 day treatment cycles. |
Top 20 of 44 competitors
HMPL-A83 is an investigational small molecule developed by HUTCHMED (China) Limited for the treatment of advanced tumors. It is being studied in oncology as a Phase 1 clinical candidate. HMPL-A83 is not yet approved for any indication and remains in early-stage clinical development.
HMPL-A83 targets CD47, a protein that functions as a checkpoint on cells. By binding CD47, the drug is designed to interfere with the CD47-mediated signaling pathway. CD47 is a protein target, and HMPL-A83 is a small molecule directed against it.
HMPL-A83 is developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company is the sponsor of the clinical program evaluating the drug in patients with advanced tumors.
HMPL-A83 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory authority. The Phase 1 program has been completed, with one trial conducted in patients with advanced tumors.
HMPL-A83 has been evaluated in one Phase 1 clinical trial, NCT05429008, titled A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm. The trial enrolled 40 patients with advanced tumors, was uncontrolled, and is now completed.
Yes, HMPL-A83 injection is another name for HMPL-A83. Both refer to the same investigational small molecule developed by HUTCHMED (China) Limited for advanced tumors. The injection formulation is the form studied in the Phase 1 trial NCT05429008.